ADRB3 and metabolic disease: Although most abundant in adipose tissue, β3-AR expression has also been documented in the urinary bladder, gallbladder, and gastrointestinal tract [151], and clinical drug development has largely focused on these tissues, with FDA-approved β3 agonists currently indicated for overactive bladder rather than metabolic disorders [152,153,154].